Anastrozole and Exemestane Interaction: Avoid | Peptide Database

Join others researching Minoxidil — share findings, ask questions, and learn from real experiences Minoxidil is an FDA-approved vasodilator originally developed in the 1970s as an oral antihypertensive medication. Its hair growth properties were discovered as a side effect, and topical formulations (2% and 5%) were subsequently approved for the treatment of androgenetic alopecia. It remains one of only two FDA-approved treatments for pattern hair loss and is available over the counter in most countries. In recent years, off-label oral minoxidil at low doses (0.625-5mg) has gained significant traction among dermatologists and the biohacker community as a more convenient and potentially more effective alternative to topical application, particularly for individuals who find the topical formulation inconvenient or who experience scalp irritation. Minoxidil is a potassium channel opener that acts on ATP-sensitive potassium channels in vascular smooth muscle cells, causing vasodilation. When applied topically or taken orally, it is converted to its active metabolite minoxidil sulfate by the enzyme sulfotransferase (SULT1A1) in hair follicle outer root sheath cells. The sulfated form opens potassium channels in dermal papilla cells and vascular smooth muscle surrounding hair follicles, increasing local blood flow and nutrient delivery. Beyond vasodilation, minoxidil upregulates vascular endothelial growth factor (VEGF) expression, extends the anagen (growth) phase of the hair cycle, increases follicle size, and stimulates the transition of resting follicles from telogen into anagen. It also has anti-fibrotic properties that may benefit the perifollicular environment. Notably, minoxidil's hair growth effects are androgen-independent, making it effective regardless of DHT levels and complementary to 5-alpha reductase inhibitors like finasteride.

Join others researching Cabergoline — share findings, ask questions, and learn from real experiences Cabergoline is a potent, long-acting dopamine D2 receptor agonist that powerfully suppresses prolactin secretion from the anterior pituitary. It is FDA-approved under the brand name Dostinex for the treatment of hyperprolactinemic disorders, including prolactin-secreting pituitary adenomas (prolactinomas). In the bodybuilding and performance enhancement community, cabergoline is considered an essential ancillary compound when running 19-nor anabolic steroids such as nandrolone (Deca-Durabolin, NPP) and trenbolone, both of which can elevate prolactin levels through progestogenic activity. Elevated prolactin causes a range of undesirable effects including gynecomastia (particularly the progesterone-mediated variant), sexual dysfunction (erectile dysfunction, decreased libido, anorgasmia), mood disturbances, and lactation. Cabergoline's exceptionally long half-life of 63-69 hours allows for convenient twice-weekly dosing, and its high affinity for D2 receptors makes it significantly more potent and better tolerated than the older dopamine agonist bromocriptine. Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypothalamic dopamine acting on these D2 receptors, and cabergoline mimics this inhibitory signal with high affinity and prolonged duration. By activating D2 receptors, cabergoline suppresses prolactin gene transcription, reduces prolactin synthesis, and inhibits prolactin release into the bloodstream. In patients with prolactinomas, cabergoline also induces tumor shrinkage by inhibiting lactotroph cell proliferation and promoting apoptosis. The drug's selectivity for D2 receptors over D1 receptors contributes to its favorable side effect profile compared to less selective dopamine agonists. In the context of 19-nor steroid use, nandrolone and trenbolone stimulate prolactin release through their progestogenic activity, and cabergoline directly counteracts this elevation by restoring dopaminergic inhibition at the pituitary level.